Close Menu

NEW YORK (360Dx) – Inanovate, a company developing blood-based tests for cancer and autoimmune diseases, said on Wednesday it closed on an initial Series C financing round that raised $3.1 million.

The company — which has offices in Sioux Falls, North Dakota, and Raleigh, North Carolina — said it anticipates a second closing of the Series C round in the second quarter of this year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.